Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?

Published on Jun 1, 2017in American Journal of Clinical Oncology1.907
· DOI :10.1097/COC.0000000000000139
Jeffrey Goldstein5
Estimated H-index: 5
(Tel Aviv Sourasky Medical Center),
Einat Even-Sapir44
Estimated H-index: 44
+ 8 AuthorsZvi Symon12
Estimated H-index: 12
Purpose:The FDA approved C-11 choline PET/computed tomography (CT) for imaging patients with recurrent prostate cancer in 2012. Subsequently, the 2014 NCCN guidelines have introduced labeled choline PET/CT in the imaging algorithm of patients with suspected recurrent disease. However, there is only
📖 Papers frequently viewed together
79 Citations
138 Citations
1,209 Citations
PURPOSE: To evaluate salvage pelvic nodal radiation as an alternative to androgen deprivation therapy (ADT) in patients with biochemical failure and lymph node recurrence following salvage prostate fossa radiation. METHODS: Six patients with biochemical failure and lymph node recurrence following prostate fossa radiation were treated with salvage pelvic nodal radiation therapy. A gross target volume was contoured using Choline PET/CT, CT, or MRI imaging. The clinical target volume included pelvi...
1 CitationsSource
#1Niccolo Passoni (UniSR: Vita-Salute San Raffaele University)H-Index: 23
#2Nazareno Suardi (UniSR: Vita-Salute San Raffaele University)H-Index: 67
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 96
view all 9 authors...
Abstract Objective Positron emission tomography (PET)/computed tomography (CT) has been shown to be a valid tool in detecting lymph node (LN) metastases in men with biochemical recurrence after radical prostatectomy. We assessed its validity in detecting a single positive LN at pathologic examination in regard to an increasing interest in lesion-targeted salvage therapies. Methods and materials We included 46 patients with biochemical recurrence after radical prostatectomy and a single positive ...
65 CitationsSource
#1Sanoj Punnen (UCSF: University of California, San Francisco)H-Index: 16
#1Sanoj Punnen (UCSF: University of California, San Francisco)H-Index: 10
Last. Stephen J. Freedland (Duke University)H-Index: 96
view all 8 authors...
Context: Despite excellent cancer control with the treatment of localized prostate cancer (PCa), some men will experience a recurrence of disease. The optimal management of recurrent disease remains uncertain. Objective: To systematically review recent literature regarding management of biochemical recurrence after primary treatment for localized PCa.
100 CitationsSource
#1James L. Mohler (Roswell Park Cancer Institute)H-Index: 71
#2Philip W. Kantoff (Brigham and Women's Hospital)H-Index: 134
Last. Maria Ho (National Comprehensive Cancer Network)H-Index: 15
view all 31 authors...
Abstract The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Pan...
89 CitationsSource
#1Ulrike SchickH-Index: 23
#2Sandra JorcanoH-Index: 13
Last. Raymond MiralbellH-Index: 62
view all 9 authors...
Background. Substantial survival may be observed with oligometastatic prostate cancer. Combining androgen deprivation (AD) and high-dose external beam radiotherapy (RT) to isolated regional or distant lesions may be proposed for these patients and the outcome of this strategy is the purpose of the present report. Material and methods. From 2003 to 2010, 50 prostate cancer patients were diagnosed with synchronous (n � 7) or metachronous (n � 43) oligometastases (OM). Among the relapsing patients,...
109 CitationsSource
#1Marcelo MamedeH-Index: 19
#2Francesco CeciH-Index: 24
Last. Stefano FantiH-Index: 83
view all 13 authors...
PurposeThis study aims to evaluate the role of 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy (RP) showing prostate-specific antigen (PSA) values lower than 0.5 ng/mL.MethodsWe performed 11C-choline PET/CT in 71 consecutive patients previously treated with RP sho
58 CitationsSource
#1Ian M. Thompson (American Urological Association)H-Index: 4
#2Richard K. Valicenti (American Urological Association)H-Index: 43
Last. Martha M. Faraday (American Urological Association)H-Index: 11
view all 12 authors...
Purpose: The purpose of this guideline is to provide a clinical framework for the use of radiotherapy after radical prostatectomy as adjuvant or salvage therapy.Materials and Methods: A systematic literature review using the PubMed®, Embase, and Cochrane databases was conducted to identify peer-reviewed publications relevant to the use of radiotherapy after prostatectomy. The review yielded 294 articles; these publications were used to create the evidence-based guideline statements. Additional g...
290 CitationsSource
Purpose The aims of the study were (a) to evaluate the diagnostic role, by means of positive detection rate (PDR), of 18F-choline (CH) positron emission tomography (PET)/CT in patients with prostate cancer treated with radiotherapy, with curative intent, and suspicion of relapse during follow-up, (b) to correlate the PDR with trigger prostate-specific antigen (PSA), (c) to investigate the possible influence of androgen deprivation therapy (ADT) at the time of scan on PDR and (d) to assess distri...
38 CitationsSource
#1Kazuhiro Kitajima (Kobe University)H-Index: 31
#2Robert C. Murphy (Mayo Clinic)H-Index: 11
Last. Mark A. Nathan (Mayo Clinic)H-Index: 19
view all 3 authors...
Whole-body positron emission tomography/computed tomography (PET/CT) with [11C]- and [18F]-labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. 11C- and 18F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, especially when the serum prostate-specific antigen level is >1.0 ng/mL. 11C- and 18F-choline PET/CT have more limited roles for the ...
45 CitationsSource
Choline PET/CT has shown limitations for the detection of primary prostate cancer and nodal metastatic disease, mainly due to limited sensitivity and specificity. Conversely in the restaging of prostate cancer recurrence, choline PET/CT is a promising imaging modality for the detection of local regional and nodal recurrence with an impact on therapy management. This review highlights current literature on choline PET/CT for radiation treatment planning in primary and recurrent prostate cancer. D...
18 CitationsSource
Cited By37
#1Matteo FerrariH-Index: 18
#2Julien Renard (Geneva College)H-Index: 4
Last. Giorgio TregliaH-Index: 49
view all 6 authors...
Hybrid imaging with radiolabelled choline has been extensively used in patients with biochemical recurrent prostate cancer (BRPCa). A useful information for the clinicians could be the change of management that can be obtained by using these imaging modalities in BRPCa. Therefore, we aimed to perform a systematic review and meta-analysis to add evidence-based data in this setting. A comprehensive computer literature search of studies listed in PubMed/MEDLINE, EMBASE and Cochrane library database...
#1Sanchia S. Goonewardene (Southend University Hospital NHS Foundation Trust)
Last. Declan CahillH-Index: 14
view all 4 authors...
#1Silvi Telo (UNIBO: University of Bologna)H-Index: 2
#2Stefano Fanti (UNIBO: University of Bologna)H-Index: 83
Last. Andrea Farolfi (UNIBO: University of Bologna)H-Index: 8
view all 12 authors...
OBJECTIVE Several studies have reported about the performance of C-choline-PET/computed tomography (CT) (choline) in patients with biochemical recurrent (BCR) prostate cancer, but there is a lack of information regarding negative choline in the same clinical setting. Our aim was to retrospectively analyse negative choline in a cohort of BCR-patients with high prostate-specific antigen (PSA). METHODS AND RESULTS We retrospectively analysed all choline-scans performed at two high-volume imaging ce...
#1Lindsay HwangH-Index: 1
#2Jeremy Paluch (SC: University of Southern California)H-Index: 5
Last. Leslie K. BallasH-Index: 9
view all 6 authors...
BACKGROUND F-Fluciclovine is the most recent prostate cancer (PCa)-directed PET radiotracer approved by the US Food and Drug Administration for detection of recurrent PCa. We report the treatments and outcomes of patients at our institution with PCa recurrences detected on F-fluciclovine PET/CT. METHODS We identified men with recurrent PCa detected on F-fluciclovine PET/CT performed between 2017 and 2018 who were previously treated definitively and analyzed their patterns of care and cancer-spec...
1 CitationsSource
Last. Pilar Paredes (University of Barcelona)H-Index: 20
view all 11 authors...
Abstract Objective To assess the diagnostic capability of PET/CT with [18F]F-Fluoromethylcholine in prostate cancer (PC) with biochemical recurrence and its therapeutic impact. Material and methods We included 108 patients, diagnosed with PC with biochemical criteria for recurrence. A PET/CT choline scan was performed by dynamic pelvic and whole body study at 60 min post-tracer injection. The relationship between the positive studies and the PSA value was analysed by classifying patients into th...
#1Nuria SánchezH-Index: 5
#1Nuria SánchezH-Index: 7
Last. Pilar Paredes (University of Barcelona)H-Index: 20
view all 11 authors...
OBJECTIVE To assess the diagnostic capability of PET/CT with [18F]F-Fluoromethylcholine in prostate cancer (PC) with biochemical recurrence and its therapeutic impact. MATERIAL AND METHODS We included 108 patients, diagnosed with PC with biochemical criteria for recurrence. A PET/CT Choline scan was performed by dynamic pelvic and whole body study at 60min post-tracer injection. The relationship between the positive studies and the PSA value was analysed by classifying patients into three groups...
#1Esther MenaH-Index: 23
#2Peter C. Black (UBC: University of British Columbia)H-Index: 51
Last. Peter L. ChoykeH-Index: 140
view all 6 authors...
INTRODUCTION Prostate cancer is a common neoplasm but conventional imaging methods such as CT and bone scan are often insensitive. A new class of PET agents have emerged to diagnose and manage prostate cancer. METHODS The relevant literature on PET imaging agents for prostate cancer was reviewed. RESULTS This review shows a broad range of PET imaging agents, the most successful of which is prostate specific membrane antigen (PSMA) PET. Other agents either lack the sensitivity or specificity of P...
1 CitationsSource
#1J.M. Quesada-Olarte (Hospital Universitario La Paz)
#2Mohamad E. Allaf (Johns Hopkins University)H-Index: 58
Last. L. Martínez-Piñeiroa (Hospital Universitario La Paz)
view all 4 authors...
Abstract Introduction The clinical course of Prostate cancer (PCa) are markedly diverse, ranging from indolent to highly aggressive disseminated disease. Molecular imaging techniques are playing an increasing role in early PCa detection, staging and disease recurrence. There are some molecular imaging modalities, radiotracers agents and its performance are important in current clinical practice PCa. Objective This review summarizes the latest information regarding molecular imaging of PCa and is...
#1Jose Quesada-Olarte (Hospital Universitario La Paz)H-Index: 1
#1J.M. Quesada-Olarte (Hospital Universitario La Paz)
Last. Luis Martínez-Piñeiro (Hospital Universitario La Paz)H-Index: 24
view all 4 authors...
Resumen Introduccion El curso clinico del cancer de prostata (CaP) es marcadamente diverso, desde enfermedad indolente a enfermedad altamente agresiva y diseminada. Las tecnicas de imagen molecular estan desempenando cada vez un papel mas importante en la deteccion temprana de CaP, estadificacion y en la deteccion de recurrencia. Existen algunas modalidades de imagen molecular y agentes radiotrazadores, cuyo rendimiento es importante en la practica clinica actual de CaP. Objetivo Esta revision r...
#1Steven P. Rowe (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 32
#2Geoffrey B. Johnson (Mayo Clinic)H-Index: 22
Last. Spencer C. Behr (UCSF: University of California, San Francisco)H-Index: 18
view all 5 authors...
: A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na18F as well as more tumor-specific compounds such as 11C-choline and 18F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotra...